GUSELKUMAB IMPROVES DACTYLITIS IN PSA PATIENTS WITH INADEQUATE RESPONSE TO TNFI: DATA FROM THE PHASE 3B COSMOS TRIAL
Marzo-Ortega H, Theander E, Neuhold M, Bergmans P, Shawi M, Perate M, Contre C, Mcinnes I, Schett G (2022)
Publication Type: Conference contribution
Publication year: 2022
Journal
Publisher: BMJ PUBLISHING GROUP
City/Town: LONDON
Pages Range: 1577-1578
Conference Proceedings Title: ANNALS OF THE RHEUMATIC DISEASES
DOI: 10.1136/annrheumdis-2022-eular.1966
Authors with CRIS profile
Involved external institutions
Leeds Teaching Hospitals NHS Trust
United Kingdom (GB)
Janssen Global Services, LLC
United States (USA) (US)
Janssen Biologics BV
Netherlands (NL)
Johnson & Johnson Services, Inc.
United States (USA) (US)
University of Glasgow
United Kingdom (GB)
United Kingdom (GB)
Janssen Global Services, LLC
United States (USA) (US)
Janssen Biologics BV
Netherlands (NL)
Johnson & Johnson Services, Inc.
United States (USA) (US)
University of Glasgow
United Kingdom (GB)
How to cite
APA:
Marzo-Ortega, H., Theander, E., Neuhold, M., Bergmans, P., Shawi, M., Perate, M.,... Schett, G. (2022). GUSELKUMAB IMPROVES DACTYLITIS IN PSA PATIENTS WITH INADEQUATE RESPONSE TO TNFI: DATA FROM THE PHASE 3B COSMOS TRIAL. In ANNALS OF THE RHEUMATIC DISEASES (pp. 1577-1578). LONDON: BMJ PUBLISHING GROUP.
MLA:
Marzo-Ortega, H., et al. "GUSELKUMAB IMPROVES DACTYLITIS IN PSA PATIENTS WITH INADEQUATE RESPONSE TO TNFI: DATA FROM THE PHASE 3B COSMOS TRIAL." Proceedings of the ANNALS OF THE RHEUMATIC DISEASES LONDON: BMJ PUBLISHING GROUP, 2022. 1577-1578.
BibTeX: Download